Assay Detail

CHEMBL4199844

Review assay metadata, readout intent, target linkage, and publication context from the same page.

ADMET

Cytotoxicity against HUVEC after 72 hrs by MTT assay

ChEMBL ↗

Free Research Context This assay will appear in recent viewed items on this browser. Open the demo workspace to preview project-only review queues.

Research home Demo workspace

Target

HUVEC (CHEMBL613979) ↗

Open DB target context

Use one target anchor to keep assay intent, target linkage, and tested compound review aligned.

Loading context

HUVEC (CHEMBL613979) is the working anchor for this assay review. Loading the live Open DB target snapshot…

Primary target HUVEC

CHEMBL613979

Anchored from Assay target.

Protein identity HUVEC

Disease frame Disease evidence pending

Open the live target snapshot or evidence card before reviewing assay metadata so target fit and disease framing stay reusable.

Review focus Open DB context pending

Open the live target snapshot before relying on this target frame across surface handoff.

Open target snapshot Open evidence card Search with this context

Total Activities

Compounds Tested

Activity Types

Assay Parameters

Assay Information

Assay Type	ADMET
Organism	Homo sapiens
Cell Type	HUVEC
Confidence	1 — Organism
Curated By	Intermediate

Target

HUVEC (CHEMBL613979) ↗

Type	CELL-LINE
Organism	Homo sapiens

Publication

Discovery of an Orally Bioavailable Dual PI3K/mTOR Inhibitor Based on Sulfonyl-Substituted Morpholinopyrimidines.

Shen S, He X, Yang Z, Zhang L, Liu Y, Zhang Z, Wang W, Liu W, Li Y, Huang D, Sun K, Ni X, Yang X, Chu X, Cui Y, Lv Q, Lan J, Zhou F.
ACS Med Chem Lett (2018) 9 : 719 -724
PubMed 30034607 · DOI

Activity Statistics

Type	Count	Avg pChEMBL	Best pChEMBL
IC50	2	6.51	6.97

Compounds Tested

Compound	Name	Phase	Activities	Best pChEMBL
CHEMBL4211915	—	—	1	6.97
CHEMBL2017974	BUPARLISIB	3.0	1	6.05

Activity Data

Compound	Name	Type	Rel.	Value	Units	pChEMBL
CHEMBL4211915	—	IC50	=	108.0	nM	6.97
CHEMBL2017974	BUPARLISIB	IC50	=	886.0	nM	6.05